GlassScriptPhysician profile
Morgan Matisko
NPI 1861990269
$3,682.14
in general payments reported to CMS, 2019-2025
11 companies · $852 in 2025
The $852 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $822 · 2022: $725 · 2023: $930 · 2024: $353 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,040 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,040.06 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,110.04 | 2021-2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $535.46 | 2021-2025 | Dupixent |
| Genzyme Corporation | $459.44 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $364.23 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $333.19 | 2021 | |
| Janssen Biotech, INC. | $281.74 | 2023-2025 | Tremfya |
| Journey Medical Corporation | $225.00 | 2021-2023 | |
| Galderma Laboratories, L.P. | $183.15 | 2024-2025 | Nemluvio |
| Abbvie INC. | $114.16 | 2025 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Biofrontera INC. | $5.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Matisko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.